Nivolumab-ipilimumab prolongs OS compared to nivolumab alone or chemo in MSI-H or dMMR, unresectable or metastatic colorectal ...
In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...
The intismeran/pembrolizumab combination significantly improved relapse-free and distant metastasis-free survival in advanced ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
Updated findings from the OptimUM trials support the use of darovasertib plus crizotinib in the treatment of patients with ...
Combining adjuvant ribociclib with an NSAI improves long-term survival in HR-positive, HER2-negative early breast cancer over ...
Neoadjuvant therapy with trastuzumab deruxtecan is of only “modest” benefit in patients with HER2-low, HR+ early-stage breast ...
The addition of UV1 did not improve efficacy for olaparib, with or without durvalumab, as maintenance therapy for BRCA-wild ...
This study examines risk factors for pneumonitis in patients with metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab.
Beginning October 23, investigators will present their latest research at the ESMO Congress 2026. Here are some studies we’re keeping an eye on.
Investigators explored how patient age affects clinician-delivered information on colorectal cancer screening.
Study findings question the appropriateness of surveillance guidelines for some subtypes of non-clear cell renal cell carcinoma (nccRCC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results